Cytosolic phospholipase A 2 (cPLA 2 ), cyclooxygenase-1 (COX-1), and cyclooxygenase-2 (COX-2) regulate the formation of physiologically active prostaglandins, the production of which is known to be elevated in several renal disorders.
associated with amelioration of the disease process, while in others eicosanoids appear to have a protective effect (for reviews see (6) (7) (8) .
Among the many isoforms of phospholipase A 2 , cytosolic PLA 2 (cPLA 2 , type IV PLA 2 ) is a ubiquitously distributed 85 kDA enzyme that is activated by an increase in cytosolic Ca 2+ and by phosphorylation (9, 10) . This enzyme is implicated in numerous pathophysiological processes in the kidney, as evidenced by alterations in renal disorders such as diabetic nephropathy, glomerulonephritis, and ischemic injury (7, 11) . In addition, cPLA 2 exhibits functional properties indicative of receptor regulated PLA 2 and is thus likely to be involved in receptor-mediated eicosanoid production and intracellular signal transduction processes (12) .
Cyclooxygenase is known to exist in two isoforms, COX-1 and COX-2, which have similar structures but different physiological functions (2, 3) . COX-1 was initially considered to be the constitutive form of the enzyme, due to the fact that it is present in nearly all cell types at a relatively constant level. COX-2 has been shown to be inducible and is not normally present at significant levels (2, 3) . However, there are exceptions to this, as COX-1 may be up-regulated under certain conditions and COX-2 is known to be expressed constitutively in some cells, including those found in the developing kidney (13) (14) (15) .
Polycystic kidney disease (PKD) includes an array of cystic kidney disorders characterized by the presence of renal cysts and is the most frequently inherited nephropathy. In this disorder, abnormal growth and development of renal cysts and chronic renal interstitial inflammation and fibrosis eventually leads to renal failure. Several mutated genes responsible for PKD have been identified, and the most common proteins affected are polycystin 1 and polycystin 2 (16) (17) (18) . We have reported that the level of the arachidonic acid-rich phospholipid, phosphatidylinositol, is reduced in cystic kidneys from mice with PKD (19, 20) . Furthermore, the levels of lyso phosphatidylinositol following short-term isotope labeling are elevated in diseased kidneys, indicating that the lower levels of phosphatidylinositol observed in these kidneys may be due to increased phospholipase A activity (20) . We therefore hypothesized that the levels of cPLA 2 would be elevated in PKD kidneys. When our initial findings in PKD mice supported this (21), we further hypothesized that the next enzymes in the eicosanoid metabolic pathway, COX-1 and COX-2, also would be elevated. We tested these hypotheses by using the CD1-pcy/pcy (pcy) mouse in which decline in renal function begins in adulthood, and the Han:SPRD-cy rat in which decline in renal function occurs during the growth phase.
MATERIALS AND METHODS

Animals
The animal experimental protocol was in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and was approved by the University Animal Care and Use Committees. Animals were obtained from our colonies, which were established from breeding stock of pcy mice from V. H. Gattone II and of Han:SPRD-cy rats from B. D. Cowley, University of Kansas Medical Centre. All animals were housed in temperature (22-24°C), humidity (50-60% relative humidity), and light (12-h light/dark cycle) controlled conditions. Both male and female rats and mice were weaned between 3 and 4 weeks of age. At weaning, all experimental animals received standard lab chow and tap water, which were provided ad libitum. Mice were killed at 60, 120, or 180 days and rats were killed at 28 or 70 days. For the mice, cyst development is slow and decline in markers of renal function does not usually occur until after 6 months of age (22, 23) . In contrast, cyst growth is rapid in the rat and markers of renal function are significantly altered by 70 days of age (24, 25) . Animals were lightly anesthetized with CO 2 before decapitation and kidneys were removed, weighed, and immediately frozen in liquid nitrogen.
Laboratory Analyses
Kidneys were lyophilized to determine water content and then pulverized. The pulverized tissue was homogenized for 60 s in 100 volumes of ice-cold buffer, which contained 50 mM Tris-HCl (pH 7.2); 250 mM sucrose; 2 mM EDTA; 1 mM EGTA; 50 µM NaF; 100 µM Na orthovanadate; 1 µg/ml soybean trypsin inhibitor; 144 µM 4-(2-aminoethyl)benzene-sulfonyl fluoride; 10 mM β-mercaptoethanol; and 25 µg/ml each of aprotonin, leupeptin and pepstatin (all reagents from Sigma Chemical, St Louis, MO) (26) . The homogenate was ultra-centrifuged at 100,000 x g for 30 min at 4°C, and the supernatant removed as the cytosolic fraction. The pellet was resuspended in 15 volumes of the homogenization buffer containing 1% Triton X-100 and was placed on ice for 15 min before centrifuging at 100,000 x g for 30 min. The supernatant was then taken as the particulate fraction. Samples were stored at -80°C until analyses. Protein concentrations of the samples were determined by using Bradford Reagent (Sigma) with bovine albumin as standard (27) .
Immunoblotting
Samples were prepared for immunoblotting by using Laemmli sample buffer (0.5M Tris-HCl, glycerol, 10% SDS, β-mercaptoethanol, 1% bromophenol blue) and were electrophoresed for 2 h at 200V on 7.5% SDS-PAGE minigels with 4% stacking gels as described (26) . Following electrophoretic protein separation, the gels were soaked in transfer buffer for 10 min and the proteins were transferred onto PVDF membranes at 375 mA for 2 h. After removal from transfer apparatus, the membranes were blocked with 5% skim milk in TBS with 0.1% Tween and then incubated in either cPLA 2 -α, COX-1, or COX-2 primary anti-body solution (1:1000 primary antibody in 2% skim milk in TBS-Tween) overnight at 4°C with rocking. Two separate rabbit antibodies to cPLA 2 -α were used. One antibody was a gift from Genetics Institute (Cambridge, MA), and the other was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse antibody to COX-1 and rabbit antibody to COX-2 were purchased from Cayman Chemical Company (Ann Arbor, MI). The membranes were then washed with 0.07% Tween in TBS and incubated in secondary antibody solution at room temperature.
For cPLA 2 analyses in pcy mouse kidneys, initially the primary antibody used was from Genetics Institute and was incubated for 22 h at a dilution of 1:1000. The secondary antibody was incubated for 2 h in a 1:20,000 dilution of alkaline phosphatase conjugated goat anti-rabbit antibody (Jackson Immunoresearch, West Grove, PA). After washing in Tween/TBS and a final wash with NBT/BCIP buffer (0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl, 0.05 M MgCl 2 ), bands were visualized with NBT/BCIP reagent (Life Technologies, Rockville, MD). Bands were imaged by using the MCID system (Imaging Research, St. Catherines, Canada) to determine the relative optical densities of the bands of interest.
Results for cPLA 2 in pcy mice were confirmed by using antibody purchased from Santa Cruz Biotechnology, which had been raised to a different epitope. Primary antibody incubation was overnight at 4°C at a dilution of 1:1000 and for the secondary was 1 h at room temperature at a dilution of 1:50,000. Membranes were then incubated with Chemi Glow TM (Alpha Innotech, San Leandro, CA), and image analysis was performed by using the Fluorchem Imager (Alpha Innotech). Data from these two procedures provided similar results, and the data presented herein are means of these two analyses. For cPLA 2 analyses in the rat and for both rat and mouse COX-1 and COX-2, the latter procedure and equipment was used.
A range of protein amounts for each enzyme was loaded onto the gel to ensure that the relative quantitative comparisons could be made for results within each isoform. The amount of protein that was in the middle of the linear response and used for analyses of the enzymes of interest ranged from 3.5 to 14 µg of protein. Representative dose response graphs are shown in Figure 1 . Color molecular weight markers and protein standards for cPLA 2 (Genetics Institute) and COX-1 and COX-2 (Cayman Chemical) were used to identify the bands of interest. Negative controls included using a non-specific antibody (anti-ovalbumin) or omitting the primary or secondary antibody. Livers from pcy mice also were analyzed for cPLA 2 levels. No significant differences were found in cPLA 2 levels in pcy compared with normal control livers (data not shown).
Statistical analyses
All samples from one age and gender group were loaded on the same gel with the same amount of protein and were analyzed together. Data were analyzed by Student's t-test when the data displayed homogeneity of variance. If variances were not equal, as detected by either Levene's or Bartlett's test, significant differences were determined by using Wilcoxin's test. The mean ± SE of the normal tissue data was set at 100 ± its SE (relative to 100) and the diseased tissue data were expressed relative to the normal tissue data.
RESULTS
The presence of disease results in larger kidneys and greater renal water content in the diseased compared with normal animals, with the disease progressing at a more rapid rate in the Han:SPRD-cy rat than in the pcy mouse (22, 24) . The disease progresses similarly in males and females in the pcy mice, with the kidney weight relative to body weight more than doubling in both genders by 180 days of age (Table 1 ). In the Han:SPRD-cy rat model the disease is much more aggressive in the male animals and results in kidneys that are 2.4× larger than normal in males, but only 1.5× larger in females by 70 days of age ( Table 2 ). The increased water content in cystic kidneys reflects the accumulation of cyst fluid in these kidneys.
The results of immunoblotting to determine cPLA 2 levels in polycystic kidneys demonstrate that this enzyme is present in cytosolic and particulate fractions in both PKD mice and rats (Figs. 2a,  b) . The levels of renal cPLA 2 in the diseased mice and rats were as much as 131% higher than normal kidneys in older animals. In the mouse kidney cytosolic fraction (Fig. 3) , we found significantly higher levels of cPLA 2 in the 180 day male (93% higher, P=0.0091) and female (106% higher, P=0.0050) mice with PKD. The levels of cPLA 2 also were higher in the diseased female mice at 120 (87% higher, P=0.0012) and 60 (86% higher, P=0.0080) days of age. In the mouse particulate fraction (Fig. 4) , there were significantly higher amounts of cPLA 2 in the diseased kidneys at 180 days of age in male (127% higher, P = 0.0008) and female (131% higher, P = 0.0115) mice, at 120 days of age in male (67% higher, P =0.0341) and female mice (98% higher, P =0.0197), and at 60 days in the female mice (38% higher, P =0.0461). These alterations were also detected in male, but not female Han:SPRD-cy polycystic rats, consistent with the more rapid disease progression in male PKD rats. In the rat kidney cytosolic (Fig. 5) and particulate (Fig. 6) fractions, significant increases of cPLA 2 were found in kidneys of 70-day-old male animals compared with normals (39% higher, P=0.0031 and 110% higher, P<0.001, respectively).
Kidney COX-1 was detected only in the particulate fractions of the kidney in both rodent models (Figs. 2a, b) . Similar to the cPLA 2 data, there were higher levels of COX-1 in the diseased mouse kidneys as compared with the normals in older animals (Fig 7) . In 180-day-old mice, COX-1 levels were 87% higher in males (P=0.0209) and 86% higher in females (P=0.004). COX-1 levels also were 145% higher in 120-day-old males (P=0.0496). In Han:SPRD-cy rats, COX-1 levels were 120% higher (P=0.0080) in male 70-day-old diseased kidneys compared with normals, but were not significantly different in females at this age or in any of the 28-day-old rats ( Fig. 8) . Because both cPLA 2 and COX-1 were higher in similar amounts, the cPLA 2 /COX-1 ratio was not significantly different in normal compared with diseased kidneys in any of the animals in any age group or gender (data for rats shown in Fig. 10 ).
In contrast to cPLA 2 and COX-1, COX-2 immunoreactive protein was detected only at quantifiable levels in rat kidneys, where the levels were 58% lower (P=0.0028) in diseased kidneys compared with normals in 70-day-old males ( Figs. 2b and 9 ). This resulted in 4-5 times higher COX-1/COX-2 (P=0.0096) and cPLA 2 /COX-2 (P=0.0085) ratios in diseased kidneys compared with normals in this group of rats (Fig. 10) , whereas there was no change in these ratios in rats with lesser disease progression, namely, females and 28-day-old rats (data not shown).
DISCUSSION
These studies demonstrate that the levels of cPLA 2 and COX-1 are elevated in diseased kidneys in two rodent models of PKD, whereas COX-2 levels are lower in diseased rat kidneys as compared with normals. In general, these alterations are greater as the disease progresses, with few changes being detected in the early stages of the disease. Prostaglandins play important roles in the maintenance of kidney function in health and disease and are involved in the regulation of normal physiologic functions, including renal blood flow, GFR, urine concentration, and renin release (4) (5) (6) 28) . Alterations in the levels of cPLA 2 , COX-1, and COX-2, as well as in the production of prostaglandins and thromboxanes have been reported in numerous renal disorders and nephritic models (28) (29) (30) (31) (32) (33) (34) (35) .
Although the cPLA 2 knockout mouse appears to have no renal abnormalities under normal conditions, the ability of the knockout mouse to deal with renal disease or environmental insults remains to be elucidated (7) . There are three known isoforms of cPLA 2 , namely the α form and the recently identified β and γ forms (36) (37) (38) . Cytosolic PLA 2 -α, the isoform examined in the current study, is widely expressed in tissues, including the kidneys, and has been implicated in numerous renal pathologies (7) . Under resting conditions, cPLA 2 is present primarily in the cytosol and translocates to the perinuclear region when cells are activated. However, prolonged activation of cPLA 2 by increased [Ca 2+ ] for an extended period of time results in continued membrane localization of the enzyme (39) . If an equilibrium between cytosolic and membranebound forms of cPLA 2 is maintained in the cell, increased translocation may result in overall increased production and/or stabilization of this enzyme, resulting in higher levels in both cytosolic and particulate fractions, as observed in the more diseased PKD kidneys in this study.
Recent studies in PKD suggest that the mutated polycystin proteins are part of multiprotein complexes that link the extracellular matrix to internal cellular structural proteins and mediate cell-cell interactions (16) . Alterations in the cellular structural framework may be related to the elevated cPLA 2 levels observed in the PKD kidneys in this study, because the intermediate filament vimentin, indirectly implicated in PKD pathogenesis (16) , is one of many factors that modulate cPLA 2 activity (40).
Cytosolic PLA 2 releases arachidonic acid from the sn-2 position of glycerophospholipids, which is then available for metabolism by the COX isoforms for the next step in prostaglandin synthesis. Coordinated regulation of specific COX isoforms with cPLA 2 suggests that fatty acid metabolism by these pathways can occur independently (41) . Cytosolic PLA 2 is functionally coupled to both COX-1 and COX-2 in COS-1 cells (42) and embryonic kidney 293 cells (43) , while specifically coordinated with COX-2 in human synovial cells (44) and in macrophages (45) , and coordinated with COX-1 in glomeruli isolated from rats with anti-Thy-1 glomerulonephropathy (11). In general, cPLA 2 coupling to COX-1 is associated with immediate short-term release of arachidonic acid, and coupling to COX-2 is associated with delayed responses in which arachidonic acid is released gradually in small amounts (46) . The results of the present study indicate a coupling between cPLA 2 and COX-1 in PKD, as COX-1 and cPLA 2 levels are both higher in diseased kidneys from older models, whereas COX-2 levels are lower.
Mouse models deficient in either COX-1 or COX-2 have been used to study the roles of the COX enzymes. COX-1 knockout mice do not compensate by up-regulating COX-2 nor do COX-2 knockouts up-regulate COX-1 (14) , suggesting that these two enzymes play separate physiological roles. On the other hand, COX-1 inhibition up-regulates COX-2 expression in the rat intestine, indicating that they are not completely independent of each other (47) . In relation to the kidney, COX-1 knockouts lack gastric and kidney pathologies, but higher levels of COX-1 in PKD kidneys is consistent with increased eicosanoid production in renal disease, as has been observed in glomerulonephritis (31).
COX-2 null mice develop several renal abnormalities, including severely underdeveloped kidneys with few functional nephrons, immature small glomeruli, and an abundance of underdeveloped mesenchymal tissue (48) . Tissue-specific and time-dependent expression of COX-2 is required for normal post-natal kidney development and maintaining normal renal architecture and function (15, 49) . Higher levels of COX-2 are found in the embryonic kidney and peak again shortly after birth, with adult levels being very low (15, 50, 51) . Our studies were consistent with these findings, as COX-2 was detected in the particulate fraction in kidneys of growing rats, but not in the mice, which have almost reached adult body weight by 60 days of age. The lower levels of COX-2 in PKD kidneys also could be related to a developmental block in the latter stages of tubular maturation in this disorder (52) .
Lower COX-2 levels also may be related to some of the earliest manifestations of renal disease in PKD, namely, the inability to concentrate urine and the development of hypertension associated with altered renin-angiotensin activity. Hypertonicity results in increased COX-2 in the medullary interstitial cells (53) , so an inability to concentrate urine is consistent with lower COX-2 levels. COX-2 protein also is found in cells of the thick ascending limb and macula densa in the cortex of rat kidneys and is involved in renin secretion as well as the response to dietary salt intake (50, (54) (55) (56) (57) . COX-2 inhibition is associated with decreased renin levels and activity and there is evidence of negative regulation of cortical COX-2 by angiotensin II (13) , which is elevated in the Han:SPRD-cy rat (58, 59) .
The finding that animals with PKD have altered levels of COX-1 and COX-2 in the latter stages of the disease adds to the questions regarding treatment of renal disease patients with nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX inhibitors (60) (61) (62) . Much interest in COX-2 selective inhibitors stems from their putative ability to relieve pain and inflammation while sparing the gastrointestinal tract (2) . Further reducing the lowered COX-2 levels in PKD may reduce the elevated renin levels and hypertension in PKD and could be beneficial. However, the effect of blocking only COX-2 on the PKD kidney has not yet been tested, and results from studies of other renal disorders and in renal cells provide conflicting results on the benefit of this treatment, warranting caution in the use of these drugs at this time (30, 35, 54, (63) (64) (65) (66) (67) (68) . In addition, COX-2 inhibitors can impair renal development and may be associated with neonatal end-stage renal failure when the fetus is exposed to these inhibitors (51, 69) . Because the PKD kidney has some immature characteristics and already has lower COX-2 levels than normal, further reduction of COX-2 may worsen the disease.
The differences in these models with respect to COX-2 levels may also help explain why diets enriched in n-3 fatty acids have a more favorable effect on disease progression in the Han:SPRDcy rat than in the pcy mouse (70-73), as COX-2 metabolizes a wider range of fatty acids as substrates and oxygenates eicosapentaenoic acid and α-linolenic acid more efficiently than COX-1 (2). The effects of specific dietary fatty acid therapy or selective COX inhibitors in PKD, therefore, need to be elucidated before either can be routinely utilized in individuals with this disorder. Table 1 Kidney weight and fluid content in CD1 (normal) and CD1-pcy/pcy (polycystic) mice.
Table 2
Kidney weight and fluid content in normal and polycystic Han:SPRD-cy rats. 
